公开(公告)号：US20220023281A1

公开(公告)日：2022-01-27

申请号：US17293157

申请日：2019-11-15

Applicant: THE UNIVERSITY OF SHEFFIELD

Inventor： Gareth RICHARDS ,  Timothy M. SKERRY ,  Joseph P.A. HARRITY ,  Jean-Olivier ZIRIMWABAGABO ,  Matthew J. TOZER ,  Karl Richard GIBSON ,  Roderick Alan PORTER ,  Paul Alan GLOSSOP

IPC: A61K31/4545 ,  A61P35/00 ,  C07D471/10 ,  C07D519/00 ,  A61K31/496 ,  A61K31/437 ,  A61K31/55 ,  A61K31/439 ,  A61K45/06 ,  A61N5/10

Abstract: Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: wherein HET, R1, R2, R3, R4, R5, L, L1, X1, X2, X3 and q are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM2). Also disclosed are the compounds for use in the treatment of diseases modulated AM2, including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds; and intermediates useful in the preparation of the compounds.

公开(公告)号：US20230036854A1

公开(公告)日：2023-02-02

申请号：US17293124

申请日：2019-11-15

Applicant: THE UNIVERSITY OF SHEFFIELD

Inventor： Gareth RICHARDS ,  Timothy M. SKERRY ,  Joseph P.A. HARRITY ,  Jean-Olivier ZIRIMWABAGABO ,  Matthew J. TOZER ,  Karl Richard GIBSON ,  Roderick Alan PORTER ,  Paul Alan GLOSSOP

IPC: C07D471/10 ,  C07D519/00 ,  A61P35/00

Abstract: Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: wherein R1, R2, R4, R5, R6, R7, R8, R9, R10, Z, X1, X2, X3, L2, HET, n and q are as defined herein. The compounds are inhibitors of adrenomedullin receptor subtype 2 (AM2). Also disclosed are the compounds for use in the treatment of diseases modulated AM2, including proliferative diseases such as cancer; pharmaceutical compositions comprising the compounds; methods for preparing the compounds; and intermediates useful in the preparation of the compounds.